Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 25;9(11):2214.
doi: 10.3390/microorganisms9112214.

Ultrasensitive Detection of SARS-CoV-2 Spike Proteins Using the Thio-NAD Cycling Reaction: A Preliminary Study before Clinical Trials

Affiliations

Ultrasensitive Detection of SARS-CoV-2 Spike Proteins Using the Thio-NAD Cycling Reaction: A Preliminary Study before Clinical Trials

Yuta Kyosei et al. Microorganisms. .

Abstract

To help control the global pandemic of coronavirus disease 2019 (COVID-19), we developed a diagnostic method targeting the spike protein of the virus that causes the infection, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We applied an ultrasensitive method by combining a sandwich enzyme-linked immunosorbent assay (ELISA) and the thio-nicotinamide adenine dinucleotide (thio-NAD) cycling reaction to quantify spike S1 proteins. The limit of detection (LOD) was 2.62 × 10-19 moles/assay for recombinant S1 proteins and 2.6 × 106 RNA copies/assay for ultraviolet B-inactivated viruses. We have already shown that the ultrasensitive ELISA for nucleocapsid proteins can detect ultraviolet B-inactivated viruses at the 104 RNA copies/assay level, whereas the nucleocapsid proteins of SARS-CoV-2 are difficult to distinguish from those in conventional coronaviruses and SARS-CoV. Thus, an antigen test for only the nucleocapsid proteins is insufficient for virus specificity. Therefore, the use of a combination of tests against both spike and nucleocapsid proteins is recommended to increase both the detection sensitivity and testing accuracy of the COVID-19 antigen test. Taken together, our present study, in which we incorporate S1 detection by combining the ultrasensitive ELISA for nucleocapsid proteins, offers an ultrasensitive, antigen-specific test for COVID-19.

Keywords: COVID-19; SARS-CoV-2; antigen test; spike protein; thio-NAD cycling; ultrasensitive ELISA.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic representation of a thio-NAD cycling ELISA for SARS-CoV-2 S1 proteins. Two antibodies used in ELISA specifically target the S1 protein. The first antibody is used to immobilize the protein, whereas the second antibody is labeled with alkaline phosphatase, which hydrolyzes a substrate containing phosphate. The hydrolyzed substrates are used in the thio-NAD cycling that employs a main enzyme (dehydrogenase) and its coenzymes (NADH and thio-NAD). Thio-NADH accumulates in a triangular manner and can be measured at 405 nm.
Figure 2
Figure 2
Linear calibration curves of SARS-CoV-2 S1 proteins by thio-NAD cycling ELISA. Three datasets measured by 3 investigators are presented as (AC). The absorbance was obtained from a 40 min cycling reaction time. Each investigator performed 3 replicate experiments. The dots show the measured plots, and the lines show those obtained by the least-squares method. The antigen was applied in the range of 31.25–1000 pg/mL.
Figure 3
Figure 3
Detection of S1 proteins in UVB-inactivated SARS-CoV-2. Because a SARS-CoV-2 virus contains single-stranded RNA, the RNA copies in the x-axis correspond to the number of viruses. Three datasets measured by 3 investigators are presented as (AC). The absorbance was obtained from a 60 min cycling reaction time. Each investigator performed 3 replicate experiments. Error bars indicate the standard deviation. The 3 investigators consistently obtained signals that were higher than the blank at concentrations over 2.6 × 106 RNA copies/assay. * p < 0.05, ** p < 0.01 compared with the value of blank by one-way ANOVA with a post-hoc Tukey test.

Similar articles

Cited by

References

    1. Ito E., Iha K., Yoshimura T., Nakaishi K., Watabe S. Early diagnosis with ultrasensitive ELISA. Adv. Clin. Chem. 2021;101:121–133. doi: 10.1016/bs.acc.2020.06.002. - DOI - PubMed
    1. Prajapat M., Sarma P., Shekhar N., Avti P., Sinha S., Kaur H., Kumar S., Bhattacharyya A., Kumar H., Bansal S., et al. Drug targets for corona virus: A systematic review. Indian J. Pharmacol. 2020;52:56–65. doi: 10.4103/ijp.IJP_115_20. - DOI - PMC - PubMed
    1. Premkumar L., Segovia-Chumbez B., Jadi R., Martinez D.R., Raut R., Markmann A., Cornaby C., Bartelt L., Weiss S., Park Y., et al. The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients. Sci. Immunol. 2020;5:eabc8413. doi: 10.1126/sciimmunol.abc8413. - DOI - PMC - PubMed
    1. Shah V.K., Firmal P., Alam A., Ganguly D., Chattopadhyay S. Overview of immune response during SARS-CoV-2 infection: Lessons from the past. Front. Immunol. 2020;11:1949. doi: 10.3389/fimmu.2020.01949. - DOI - PMC - PubMed
    1. Almehdi A.M., Khoder G., Alchakee A.S., Alsayyid A.T., Sarg N.H., Soliman S.S.M. SARS-CoV-2 spike protein: Pathogenesis, vaccines, and potential therapies. Infection. 2021;49:855–876. doi: 10.1007/s15010-021-01677-8. - DOI - PMC - PubMed

LinkOut - more resources